Trial Profile
Phase I trial of CEL-SCI Corporation's rheumatoid arthritis vaccine, CEL 2000.
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Jun 2018
Price :
$35
*
At a glance
- Drugs Rheumatoid arthritis vaccine (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 03 May 2018 According to an IMV media release, Immunovaccine has changed its name to IMV.
- 10 Nov 2010 New trial record